Supplementary Materials Data Availability Statement Data sharing is not applicable to this article as no new data were created or analyzed in this study.
We analyzed the weekly incidence of side effects during the first two weeks that a participant recorded a given dose amount, using a Bayesian logistic mixed-effects model
Currently licensed weight management medications in the UK include: Orlistat (lipase inhibitor that reduces fat absorption) Wegovy (semaglutide injection) for chronic weight management (typically BMI 35 kg/m, or 30 kg/m with weight-related comorbidities, via specialist weight management services) [13] Saxenda (liraglutide injection) , another GLP-1 receptor agonist (typically BMI 35 kg/m, or 30 kg/m with weight-related comorbidities) Mysimba (naltrexone/bupropion) is licensed but not routinely commissioned by the NHS [15] [16] NICE recommends lower BMI thresholds (typically 2.5 kg/m lower) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds
In turn, these actions lead to you feeling full, resulting in weight loss and a decrease in appetite
